GleamWall
中文EN

PGEN PRECIGEN, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1356090 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY109.9%
TTM EPS YoY107.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin21.4%
Net margin15.6%
FCF margin-47.4%
EBITDA margin23.9%

Returns

ROE38.8%
ROA12.7%
ROIC (approx.)23.5%
Asset turnover0.82x

Leverage & solvency

Liabilities / assets60.5%
Debt / equity1.12x
Current ratio5.58x
Interest coverage2.85x

Cash quality & payout

Operating cash flow / net income-3.00x
Accruals ratio50.9%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$74.15M$54.98M$23.25M$4.57M$2.92M$856,000$1.34M—
R&D expense$6.63M$7.28M$5.64M$6.99M$12.38M$11.49M$10.48M—
SG&A expense$22.36M$22.25M$21.05M$17.64M$23.99M$16.13M$12.36M—
Operating income$38.65M$22.64M-$5.99M-$21.67M-$34.48M-$31.76M-$22.60M—
Interest expense$3.00M$2.95M$2.91M$2.96M$902,000$0$1,000—
Pretax income$35.97M$20.07M-$7.93M-$23.50M-$146.34M-$26.64M-$54.15M-$19.81M
Income tax$200,000$0$0$0$0$3,000$0-$87,000
Net income$35.77M$20.07M-$7.93M-$23.50M-$146.34M-$26.64M-$54.15M-$19.73M
EBITDA$39.44M$23.42M-$4.89M-$20.53M-$34.00M-$31.45M-$21.97M—
EPS (basic)0.100.06-0.02—-1.06-0.09-0.18—
EPS (diluted)0.080.05-0.02—-1.06-0.09-0.18—
Weighted avg. shares (diluted)421.16M413.69M354.29M—307.17M296.43M293.88M—
Balance sheet
Cash & equivalents$14.96M$16.33M$7.48M$30.23M$14.32M$13.76M$6.06M$29.52M
Short-term investments$31.11M$21.88M$48.77M$67.62M$106.81M$45.99M$74.18M$68.39M
Receivables$96.49M$71.87M$26.40M$3.92M$580,000$327,000$751,000$926,000
Inventory$22.91M$20.25M$14.72M$9.58M$3.06M——$0
Current assets$171.76M$134.38M$101.67M$115.23M$129.60M$62.76M$84.60M$102.41M
PP&E, net$13.29M$12.80M$13.22M$13.76M$14.81M$14.70M$14.67M$13.83M
Goodwill$15.23M$15.23M$15.23M$15.23M$15.23M$15.23M$19.14M$19.14M
Intangibles$2.23M$2.54M$2.86M$3.18M$3.50M$3.82M$4.14M$4.46M
Total assets$212.10M$170.30M$138.63M$155.50M$171.26M$101.90M$128.79M$145.27M
Current liabilities$30.79M$29.35M$21.10M$37.31M$32.07M$23.19M$23.99M$21.52M
Long-term debt$94.26M$93.88M$93.52M$93.17M$92.89M——$0
Total debt$94.26M$93.88M$93.52M$93.17M$92.89M——$0
Total liabilities$128.31M$126.72M$118.39M$134.59M$129.40M$107.79M$113.33M$78.53M
Shareholders' equity$83.79M$43.58M$20.23M$20.91M$41.87M-$36.78M-$14.06M$38.51M
Net debt$79.30M$77.55M$86.04M$62.94M$78.57M——-$29.52M
Shares outstanding358.54M358.01M355.90M353.91M353.81M297.85M295.14M292.87M
Cash flow statement
Operating cash flow$11.88M-$17.81M-$43.83M-$23.46M-$29.07M-$18.98M-$16.32M-$8.24M
Capital expenditure$435,000$392,000$258,000$18,000$389,000$966,000$622,000$1.03M
Free cash flow$11.45M-$18.20M-$44.09M-$23.48M-$29.46M-$19.94M-$16.95M-$9.27M
Investing cash flow-$13.97M$26.69M$20.97M$39.87M-$63.39M$28.44M-$6.46M-$65.37M
Financing cash flow$733,000-$33,000$109,000-$514,000$93.01M-$1.77M-$679,000$78.40M
Depreciation & amortization$793,000$782,000$1.10M$1.14M$485,000$312,000$629,000$661,000
Stock-based compensation$3.78M$3.31M$3.01M$2.16M$4.39M$1.64M$2.68M$2.87M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.